Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD
Schematic overview of the kynurenine metabolic pathway. The kynurenine metabolic pathway starts with the ingestion of TRP through diet. Via the uptake by large neutral amino acid transporters, TRP crosses the blood–brain barrier []. From here on, TRP is either used for protein synthesis, in the minor serotonergic metabolic pathway or for the formation of kynurenine and its metabolites. KYN can either be catalyzed to ANA, KYNA or 3-HK. In turn, 3-HK is then either catalyzed into XA or to 3-hydroxyanthranilic acid (3-HANA) and ACMS, an intermediate product which then results in spontaneous conversion to QUIN or metabolization to PA. Eventually, QUIN is metabolized to NA or NAD+. The kynurenine pathway leads to the formation of three neuroactive compounds: the neuroprotective KYNA (NMDA receptor antagonist) in astrocytes and the formation of neurotoxic compounds 3-HK, 3-HANA (both generate ROS) and QUIN (NMDA receptor agonist and generates ROS) in microglia [,]. Abbreviations: TRP = tryptophan, KYN = kynurenine, ANA = anthranilic acid, KYNA = kynurenic acid, 3-HK = 3-hydrokynurenine, XA = xanthurenic acid, 3-HANA = 3-hydroxyanthranilic acid, ACMS = 2-amino-3-carboxymuconate 6-semialdehyde, QUIN = quinolinic acid, PA = picolinic acid, NA = nicotinic acid, NAD+ = nicotinamide-adenine-dinucleotide, IDO = indoleamine 2,3-dioxygenase, TDO = tryptophan 2,3-dioxygenase, KYNU = kynureninase, KAT = kynurenine aminotransferase, KMO = kynurenine 3-monooxygenase, 3-HAO = 3-hydroxyanthranillic acid dioxygenase, ACMSD = 2-amino-3-carboxymuconate 6-semialdehyde decarboxylase, QPRT = quinolinate phosporibosyltransferase, NMNAT = nicotinamide mononucleotide adenylyl transferase, NMDA = N-methyl-D-aspartate, ROS = reactive oxygen species. Image created with BioRender and adapted from Schwieler et al. [].